Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Gilead Sciences, Inc. and its officers or directors [1] Company Developments - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns related to decreases in CD4+ T-cell and absolute lymphocyte counts in trial participants [3] - Following the announcement of the clinical hold, Gilead's stock price decreased by $2.91, or 2.58%, closing at $110.09 per share on the same day [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Group 1 - The investigation by Pomerantz LLP concerns potential securities fraud or unlawful business practices by Vera Bradley and its officers or directors [1] - Vera Bradley reported disappointing financial results for Q1 of fiscal year 2026, with CEO Jackie Ardrey acknowledging the need for significant improvements to achieve positive growth [3] - Following the announcement of poor financial results, Vera Bradley's stock price dropped by $0.45, or 19.15%, closing at $1.90 per share on June 11, 2025 [4] Group 2 - Vera Bradley announced key leadership changes, including the departure of CEO Jackie Ardrey at the end of July 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving CTO Realty Growth, Inc. following a report by Wolfpack Research that accused the company of misleading investors regarding dividend sustainability and engaging in questionable financial activities [1][3]. Group 1: Investigation and Allegations - Pomerantz LLP is representing investors of CTO Realty Growth, Inc. in an investigation concerning possible securities fraud or other unlawful business practices [1]. - Wolfpack Research published a report on June 25, 2025, alleging that CTO misled investors about its dividend sustainability, leading to a significant drop in stock price [3]. - Following the release of the Wolfpack report, CTO's stock price decreased by $0.98 per share, or 5.42%, closing at $17.10 per share on the same day [3]. Group 2: Company Background - CTO Realty Growth, Inc. is listed on the NYSE under the ticker symbol CTO [1]. - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering substantial damages for victims of securities fraud [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the company overbilled customers for ad impressions served to declared bots and that its risk disclosures were materially false and misleading [5]. - The lawsuit asserts that the defendants' positive statements about DoubleVerify's business lacked a reasonable basis, leading to investor damages when the true details became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

LOS ANGELES, July 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Reddit, Inc. (“Reddit” or the “Company”) (NYSE: RDDT) securities between October 29, 2024 and May 20, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR REDDIT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

Core Viewpoint - Investors in 3D Systems Corporation have the opportunity to lead a securities fraud class action lawsuit due to alleged misrepresentations by the company regarding its financial health and business operations [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from August 13, 2024, to May 12, 2025, 3D Systems failed to disclose significant information, including the understatement of weakened customer spending's impact on the business and the overstatement of the company's resilience in tough industry conditions [2]. - It is alleged that updated milestone criteria in the United Partnership would adversely affect the revenue from the Regenerative Medicine Program [2]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses are encouraged to participate in the ongoing lawsuit before the lead plaintiff deadline of August 12, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, but allegedly misrepresented the nature of this partnership and compliance with FDA regulations [3][4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share within three days [5].

Core Viewpoint - 3D Systems Corporation is facing a class action lawsuit due to significant financial losses and misleading statements made by the company regarding its business performance and outlook during the Class Period from August 13, 2024, to May 12, 2025 [1][5]. Financial Performance - On March 26, 2025, 3D Systems reported its Q4 and full-year 2024 results, missing consensus estimates for non-GAAP earnings-per-share and sales revenue, attributing the shortfall to lower hardware systems sales caused by macroeconomic factors [2]. - The company experienced a revenue reduction of $9 million in Q4 due to changes in accounting estimates related to its Regenerative Medicine program [2]. - Following this announcement, the stock price dropped by $0.57, or 21%, closing at $2.15 per share on March 27, 2025 [2]. - On May 12, 2025, 3D Systems released its Q1 2025 results, again missing estimates, primarily due to a decline in material sales linked to inventory management issues in its Healthcare Solutions segment [3]. - The company withdrew its full-year 2025 outlook, citing ongoing softness in customer capital spending and macroeconomic uncertainty [3]. - The stock price fell further by $0.68, or 26.6%, closing at $1.87 per share on May 13, 2025 [4]. Lawsuit Details - The class action lawsuit alleges that 3D Systems made materially false and misleading statements and failed to disclose adverse facts about its business and prospects during the Class Period [5]. - Specific allegations include the understatement of the impact of weakened customer spending and the overstatement of the company's resilience in challenging conditions [5]. - The lawsuit claims that the updated milestone criteria in the United Partnership negatively affected the revenue from the Regenerative Medicine Program [5].

Core Viewpoint - A class action securities lawsuit has been filed against DoubleVerify Holdings, Inc. alleging securities fraud that negatively impacted investors between November 10, 2023, and February 27, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited [2] - It is alleged that DoubleVerify's ability to monetize its Activation Services was constrained due to the high costs and time required for technology development for closed platforms [2] - The complaint states that monetization of DoubleVerify's Activation Services on certain closed platforms would take several years [2] - Competitors of DoubleVerify were reportedly better positioned to integrate AI into their offerings on closed platforms, affecting DoubleVerify's competitive edge and profitability [2] - The company is accused of systematically overbilling customers for ad impressions served to declared bots from known data center server farms [2] - The risk disclosures provided by DoubleVerify were claimed to be materially false and misleading, presenting adverse facts as mere possibilities [2] - As a result of these issues, the lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially false or lacked a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses in DoubleVerify Holdings, Inc. during the specified timeframe have until July 21, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]